fluspirilene
Small moleculeexperimental
Fluspirilene is a diphenylbutylpiperidine typical antipsychotic drug, used for the treatment of schizophrenia. It is administered intramuscularly. It was discovered at Janssen Pharmaceutica in 1963. A 2007 systematic review investigated the efficacy of fluspirilene decanoate for people with schizophrenia: — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
1
Earliest trial started Nov 1, 2014 (NCT02307396)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Dopamine D2 receptorINHIBITOR
DRD2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2- Mol. weight
- 475.58 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFluspirilene ↗
- ChEMBLCHEMBL46516 ↗
Also known as
- fluspirilen
- fluspirilene
- fluspirilene
- fluspirilene
- fluspirilene
- fluspirilene
- fluspirilene
- fluspirilene
- fluspirilene
- fluspirilene
- fluspirileno
- fluspirileno
- fluspirilenum
- fluspirilenum
- fluspiriline
- imap
- imap
- imap
- mcn-jr-6218
- mcn-jr-6218
- r 6218
- r-6218
- r-6218
- r-6218
- redeptin
- redeptin
- redeptin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
| NCT02307396 | Phase 4 | Nov 1, 2014 | Technical University of Munich |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Technical University of Munich | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1